Invesco Dynamic Biotechnology & Genome ETF company info

What does Invesco Dynamic Biotechnology & Genome ETF do?
Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is an exchange-traded fund that focuses on the dynamic biotechnology and genome sector. It aims to invest in companies at the forefront of medical and scientific breakthroughs, targeting those involved in the research, development, manufacture, and distribution of various biotechnological products and services. The ETF seeks to provide investors with exposure to advancements in genetics, bioinformatics, and related technologies, aiming to capture the growth potential within the rapidly evolving biotech industry. Through a strategic blend of both large and small-cap companies, Invesco Dynamic Biotechnology & Genome ETF strives to balance risk and reward, capitalizing on innovation and scientific progress to achieve long-term investment objectives.
Invesco Dynamic Biotechnology & Genome ETF company media
Company Snapshot

Is Invesco Dynamic Biotechnology & Genome ETF a public or private company?

key
Ownership
Public

How many people does Invesco Dynamic Biotechnology & Genome ETF employ?

people
Employees
5,025

What sector is Invesco Dynamic Biotechnology & Genome ETF in?

pie chart
Sector
ETF

Where is the head office for Invesco Dynamic Biotechnology & Genome ETF?

location pin
Head Office
Atlanta, United States

What year was Invesco Dynamic Biotechnology & Genome ETF founded?

founded flag
Year Founded
2005
What does Invesco Dynamic Biotechnology & Genome ETF specialise in?
/Exchange Traded Fund /Biotechnology Investments /Genome Sector /Risk Management /Portfolio Diversification /Investment Services

What are the products and/or services of Invesco Dynamic Biotechnology & Genome ETF?

Overview of Invesco Dynamic Biotechnology & Genome ETF offerings
Investment in biotechnology companies involved in the development and production of biopharmaceuticals and vaccines.
Support for genomic research firms working on gene editing and genetic sequencing technologies.
Funding for innovative drug discovery and development projects targeting rare diseases.
Backing of companies focused on cell therapy, including stem cell research and regenerative medicine.
Investment in firms developing personalized medicine solutions through advanced diagnostics and therapies.
Support for biotech startups focusing on next-generation treatments and healthcare solutions.